Your browser doesn't support javascript.
loading
Progress of programmed death-1/programmed death-1 ligand in esophageal cancer / 肿瘤研究与临床
Cancer Research and Clinic ; (6): 776-780, 2017.
Article in Chinese | WPRIM | ID: wpr-667758
ABSTRACT
Programmed death-1 (PD-1) occurs widely in a variety of human immune cells and tumor cells. When PD-1 is combined with programmed death-1 ligand (PD-L1), T-lymphocyte will be exhausted eventually resulting in tumor immune escape. Experiments in vitro and in vivo have demonstrated that inhibiting the binding of PD-1 with PD-L1, and blocking downstream signaling pathways can enhance endogenous anti-neoplastic immune effects. The expression of PD-1/PD-L1 is related to the clinical stage and prognosis of esophageal cancer patients, which may become the clinical biomarkers, serving as a new target for cancer immunotherapy.This paper reviews the relationship between PD-1/PD-L1 and esophageal cancer as well as the related treatment progress.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Cancer Research and Clinic Year: 2017 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Cancer Research and Clinic Year: 2017 Type: Article